Evaluating the presence of *Mycoplasma hyorhinis*, *Fusobacterium nucleatum*, and *Helicobacter pylori* in biopsies of patients with gastric cancer

Camila do Nascimento Araujo¹, Aline Teixeira Amorim¹, Maysa Santos Barbosa¹, Julieta Canjimba Porto Lucas Alexandre², Guilherme Barreto Campos¹,³, Cláudia Leal Macedo⁴, Lucas Miranda Marques¹,³*, and Jorge Timenetsky¹

Abstract

**Background:** Gastric cancer is the third leading cause of cancer-related deaths worldwide and has been associated with infections that may promote tumour progression. Accordingly, we analysed the presence of Mollicutes, *Mycoplasma hyorhinis*, *Fusobacterium nucleatum* and *Helicobacter pylori* in gastric cancer tissues and evaluated their correlation with clinicopathological factors.

**Methods:** Using a commercial kit, DNA were extracted from 120 gastric samples embedded in paraffin: 80 from patients with gastric cancer and 40 from cancer free patients, dating from 2006 to 2016. Mollicutes and *H. pylori* were detected by PCR; *F. nucleatum* and *M. hyorhinis* were detected by qPCR, together with immunohistochemistry for the latter bacteria.

**Results:** Mollicutes were detected in the case and control groups (12% and 2.5%) and correlated with the papillary histologic pattern (*P* = 0.003), likely due to cell transformation promoted by Mollicutes. *M. hyorhinis* was detected in the case and control group but was not considered a cancer risk factor. *H. pylori* was detected at higher loads in the case compared to the control group (8% and 22%, *P* = 0.008) and correlated with metastasis (*P* = 0.024), lymphatic invasion (*P* = 0.033), tumour of diffused type (*P* = 0.028), and histopathological grading G1/G2 (*P* = 0.008). *F. nucleatum* was the most abundant bacteria in the case group, but was also detected in the control group (26% and 2.5%). It increased the cancer risk factor (*P* = 0.045, OR = 10.562, CI95% = 1.057–105.521), and correlated with old age (*P* = 0.030) and tumour size (*P* = 0.053). Bacterial abundance was significantly different between groups (*P* = 0.001).

**Conclusion:** Our findings could improve the control and promote our understanding of opportunistic bacteria and their relevance to malignant phenotypes.

**Keywords:** Mollicutes, *Mycoplasma hyorhinis*, *Fusobacterium nucleatum*, *Helicobacter pylori*, Gastric cancer

Background

The mortality rates due to neoplasia exceed those caused by coronary heart disease or stroke, and the highest rates are reported in low- to middle-income households [1]. Globally, gastric cancer is the fifth most diagnosed and the third leading cause of cancer-related deaths.
that mainly affects men over 50 years of age. Its prevalence and prognosis vary considerably between racial and socioeconomic groups. In Brazil, mortality rates due to gastric cancer rank fourth among men and sixth among women [1, 2]. Gastric cancer affects different sites in the stomach with macroscopic variations and distinct histological patterns. According to Lauren's classification, stomach cancer can be divided into intestinal type and diffuse type [3]. The development of stomach tumours has primarily been associated with an individual's genetics, environmental factors, and infection with pathogens that induce persistent inflammation. For example, Helicobacter pylori is a pathogen that induces peptic ulcers, neutralises gastric acid, and, with their cag pathogenicity island, maintains a tumour-permissive microenvironment in the gastric mucosa [4].

Opportunistic microorganisms, such as Mollicutes and Fusobacterium nucleatum, are not considered to be type I carcinogens. However, given their prevalence in tumour tissues, their potential roles as oncobacteria deserve investigation. F. nucleatum, a Gram-negative, anaerobic, biofilm-forming, non-spore-forming and non-mobile bacillus, occurs at equilibrium in the oral-gastrointestinal tracts and participates in the health and homeostasis of the oral site [5]. F. nucleatum has also been associated with extraoral diseases such as appendicitis and intestinal inflammation [5]; has been reported in oral, head and neck, cervical and gastric carcinoma tissues; and is commonly associated with colorectal cancer, where it induces a worse prognosis by promoting resistance to chemotherapy [6, 7]. The association of F. nucleatum with malignant lesions can be explained by microsatellite instability, alteration of the CpG island methylator phenotype (CIMP), and mutations in the BRAF, KRAS, and TP53 genes [8]. F. nucleatum can migrate out of the oral site via an oral-gastrointestinal route or haematogenously in a Fap2 adherin-dependent manner. Fap2 is an adhesin unique to oral Fusobacteria that binds to GalGalNac (a sugar residue overexpressed in tumour tissue) or to the T cell immunoglobulin and ITIM domain (TIGIT) (a receptor of natural killer cells and lymphocytes), inhibiting the cytotoxic function of these cells and promoting a conducive environment for bacteria and tumour cells [9].

The human microbiome harbours not only F. nucleatum, but also bacteria of the Mollicutes class that may cause or be associated with host immunosuppression [5, 10], and have been detected in tissues of patients with chronic gastritis, local inflammation, and neutrophil accumulation [11]. Mollicutes belong to a heterogeneous group of microorganisms that are present in humans, animals, insects, and plants [10]. Most pathogenic species in humans and animals belong to the order Mycoplasmatales, with 160 Mycoplasma species and 8 Ureaplasma species [12]. Mycoplasma species, like the porcine M. hyorhinis, are common cell culture contaminants. Mycoplasma hyorhinis can, reportedly, invade mammalian immune cells and has been detected in gastric carcinoma tissues [13, 14].

Mycoplasma hyorhinis has been implicated in several swine diseases [15], with severe pathogenicity, mortality rates, and subsequent economic losses. Attempts to minimise these impacts with antibiotics promote the development of drug resistant M. hyorhinis strains, which infect the human stomach via the consumption of porcine products [11, 15]. A previous report identified M. hyorhinis in 56% of a gastric cancer [16]. Its association with gastric cancer is more common than with other gastric diseases [17] where it is able to induce different profiles that cause chronic superficial gastritis, gastric ulcers, and intestinal metaplasia [16]. Lipoprotein p37, a component of M. hyorhinis that possesses a transport system similar to the periplasmic transport systems of Gram-negative bacteria, is believed to promote cell motility and invasion, consequently exacerbating carcinogenesis and metastasis [18, 19]. These features have been identified both in vitro and in vivo and were associated with the phosphorylation of epidermal growth factor receptor (EGFR) and extracellular signal-regulated kinase 1/2 (ERK1/2) [13]. The EGF binding/receptor system appears to be involved in regulating gastric mucosal proliferation and the progression of gastric carcinomas [20]. M. hyorhinis infection, or the presence of p37 alone, might induce the phosphorylation of PI3k and AKT, which are EGFR-dependent. Activation of the EGFR-PI3K-AKT pathway is related to the regulation of metabolism, growth, survival, and cell motility; the dysregulation of this pathway has been linked to tumorigenesis and angiogenesis [21].

Infection with M. hyorhinis and the p37 protein can potentially promote gastric cancer development, though the underlying mechanism remains unclear and needs further elucidation [13, 21]. Based on the strong association between gastric cancer and infectious agents, we evaluated the relationship between specific clinical variables and infection with Mollicutes as well as F. nucleatum and H. pylori. Our study group consisted of individuals with or without gastric cancer from Vitória da Conquista, Bahia (BA), Brazil. Not all samples positive for Mollicutes were positive for M. hyorhinis, indicating that other mycoplasma species may be present in the gastric tissue.

Methods
Study population
We performed a retrospective study assessing formalin-fixed paraffin-embedded (FFPE) gastric fragment samples collected from 2006 to 2016. These samples were obtained from a laboratory of pathological anatomy and...
DNA extraction from formalin-fixed paraffin-embedded (FFPE) gastric fragment samples

Due to the difficulties in recovering nucleic acids from FFPE samples and the diversity of protocols available in the literature, we selected an optimal method based on assay duration and the viability of extracted DNA. Four methods were in-house and were assessed with and without prior xylol dewaxing, and two other methods were performed using commercial kits and were tested with and without xylol and mineral oil dewaxing. After dewaxing the samples, the extraction methods were tested with different digestion buffers, as described:

- **Dewaxing with Xylol** [24]: This was performed for in-house methods before DNA extraction. In brief, DNA samples were immersed in xylol (pH 6–7.6) at 65 °C for 10 min and then bathed in 99°, 96°, and 70° Gay-Lussac (GL) and volatilised for 30 min.
- **Dewaxing with Mineral Oil** [25]: This was performed before DNA extraction using commercial kits. Briefly, DNA samples were immersed in mineral oil, incubated for 1 min at 80 °C, and vortexed.
- **Extraction Method 1 (EM1)**: digestion buffer (pH 7.5), with 1 M Tris–HCl, 1% SDS (sodium dodecyl sulphate), and PK (proteinase K) (10 mg/mL) [24].
- **Extraction Method 2 (EM2)**: digestion buffer (pH 8.0), with 1 M NaCl, 1 M Tris–HCl, 0.5 M EDTA, 10% SDS, and PK (0.5 mg/mL) [26].
- **Extraction Method 3 (EM3)**: digestion buffer (pH 8.5), with 50 mM Tris–HCl, 1 mM EDTA, and 0.5% Tween 20 and PK (200 μg/mL) [16].
- **Extraction Method 4 (EM4)**: digestion buffer (pH 9.0), with 50 mM Tris–HCl and PK (20 mg/mL) [27].

Subsequently, samples were incubated at 95 °C for 10 min, purified using a solution of phenol/chloroform/isoamyl alcohol (25:24:1; pH 8.0), treated with ammonium acetate (7.5 M), precipitated with ice-cold ethanol followed by alcohol baths, and volatilised for 30 min [28]. Samples were homogenised with 40 μL of Tris–EDTA buffer (10 mM Tris–HCl, 1 mM EDTA, pH 8.0) and stored at −20 °C.

- **Extraction Method 5 (EM5)**: after dewaxing, DNA extraction was performed using a ReliaPrep™ FFPE gDNA Miniprep System (Promega®, Madison, WI, USA).
- **Extraction Method 6 (EM6)**: after dewaxing, DNA extraction was performed using a Macherey-Nagel® Tissue Kit (Fisher Scientific®, Fair Lawn, NJ, USA).

For each extraction method, the amount and purity of DNA were assessed spectrophotometrically (Nanospectrometer-DS-11, DeNovix®, Wilmington, DE, USA).

Molecular detection

**β-globin PCR**

The primers PC03/PC04 for the housekeeping gene (β-globin) [29] were standardised to verify the quality of the extracted genetic material. Primer sequences and the expected product size are listed in Table 1. Genomic DNA samples were amplified by PCR, and the product size was verified by performing agarose gel (2%) electrophoresis. DNA derived from frozen tissue and Si-Ha cell culture were used as positive controls, with ultrapure water employed as a negative control. All PCR reactions on FFPE extracted material were performed in duplicate.

To prepare PCR reactions, we used 50 ng/µL of purified DNA from each sample, 1 × buffer (Buffer—10 × Tris–HCl [pH 8.4], 500 mM KCl), 1.6 mM of deoxyribonucleotide triphosphate (dNTP), 1.5 mM of MgCl₂, 20,000 nM of each primer (Table 1), 0.5 U of Taq DNA polymerase (Invitrogen®, São Paulo, SP, Brazil), to achieve a final volume of 25 μL. The assays were performed in a Veriti Thermal Cycler (Applied Biosystems, São Paulo, SP, Brazil). The reaction parameters were as follows: denaturation of 95 °C for 5 min, 40 cycles at 95 °C for 1 min, with different annealing temperatures tested (54–56 °C) for 1 min, 72 °C for 1 min, a final cycle of 72 °C for 10 min, and a hold step at 4 °C.

**Mollicutes, M. hyorhinis, F. nucleatum, and H. pylori detection**

Different strains of mycoplasmata were cultured, and their DNA was extracted using a PureLink™ Genomic DNA Mini Kit (Thermo Fisher Scientific, Waltham, MA, USA). *M. hyorhinis* (ATCC 17981) was cultured in FRISS medium (pH 7.2) [30]; *M. bovis* (ATCC 19210 – AN5)
and *M. hominis* (ATCC 23114-PG-21) were cultured in SP4 medium (pH 7.4), supplemented with glucose or arginine [31]. The strains were obtained from the Mycoplasma Laboratory collection at the Institute of Biomedical Sciences, University of São Paulo, SP, Brazil.

Conventional PCRs were performed to detect 16S rRNA of Mollicutes [32], *H. pylori* [33], and *M. hyorhinis* [34]. Accordingly, 50 ng/µL of purified DNA was used for each sample, 1× buffer (Buffer—10 × Tris–HCl [pH 8.4], 500 mM KCl), 0.2 mM of deoxyribonucleotide triphosphate (dNTP), 1.5 mM of MgCl$_2$, 50,000 nM of each primer (Table 1), and 1.0 U of Taq DNA polymerase (Invitrogen®), to achieve a final volume of 25 µL. For Mollicutes, genus-specific universal primers were used instead. The assays were performed using a Veriti® Thermal Cycler (Applied Biosystems, São Paulo, SP, Brazil). The parameters for each reaction have been previously described [32–34].

Quantitative PCR was used to detect 16 s rRNA of *F. nucleatum* [35] and p37 of *M. hyorhinis* [15]. First, mycoplasmas were cultured, and the DNA was extracted according to the manufacturer’s instructions. The genomic DNA copy number was then calculated by spectrophotometry. Ten-fold serial dilutions (10$^2$–10 copies/µL) of the mycoplasma DNA standard were prepared and analysed. A standard curve was prepared for each reaction. Samples were analysed in triplicate using a 7300 Real-Time PCR System (Applied Biosystems). The reagents used were as follows: 50 ng/µL of DNA extracted by EM6, 12.5 µL of Master Mix (Applied Biosystems), 100 µM of each primer (Table 1), and 0.3 µM Taqman probe (Table 1); the final volume was 25 µL. The samples were amplified using StepOne™ software (Applied Biosystems) with the following cycles: 50 °C for 2 min, 95 °C for 10 min, 40 cycles of denaturation at 95 °C for 15 s, and annealing at 55 °C for 30 s (to detect *F. nucleatum* DNA) or 57 °C for 15 s (to detect *M. hyorhinis* DNA) and extension at 60 °C for 1 min.

**Immunohistochemistry detection**

To confirm whether there was a higher charge of *M. hyorhinis* that was not found by molecular methods, 120 4-µm-thick sample sections were assessed for *M. hyorhinis* occurrence using IHC. Si-Ha cells with or without *M. hyorhinis* coinfection were used as positive and negative controls, respectively [36]. Unstained sections of each sample were dewaxed by twice immersing them in xylol baths for 10 min, followed by rehydration in consecutive graduated ethanol baths (99°, 96°, and 70° GL) and distilled water. Peroxidase was blocked with H$_2$O$_2$ (10 vol.) for 10 min, twice, and the samples were then washed with distilled water. Antigenic recovery was carried out in an electric pressure cooker for 15 min using Trilogy™ Cell Marque solution, followed by washing with distilled water and Tris Buffered Saline (TBS; pH 7.4). The slides were incubated overnight with primary horse polyclonal antibodies against *M. hyorhinis*-7 (NIAID, Bethesda, MD; 1:100) in a darkroom at 4 °C. Next, slides were washed three times using TBS for 5 min, incubated with peroxidase-conjugated rabbit anti-horse IgG (Thermo Fisher Scientific, Waltham, MA, USA) for 30 min, and again washed with TBS. Detection was performed using

---

**Table 1**

Primer used in the PCR assay for detecting β-globin, Mollicutes, *Helicobacter pylori*, *Fusobacterium nucleatum*, and *Mycoplasma hyorhinis*

| Primer       | Sequence (5′–3′)                        | Location     | Amplicons | Ref  |
|--------------|----------------------------------------|--------------|-----------|------|
| PC03         | ACACAACGTGTTCTACAG                    | nt 1575-1594 | 110 bp    | [29] |
| PC04         | CAACCTCATCCAGTTTCCAC                  | nt 1684-1669 |           |      |
| GPO3         | GGGGACACCAACACGATGATACCTC             | nt 221-245   | 270 bp    | [32] |
| MGSO         | TGCACTATGCTATACCTGTAACCT              | nt 491-465   |           |      |
| JW21         | GCGACCTCTGGCAACACATTAC                | nt 691-710   | 138 bp    | [33] |
| JW22         | CTGTTAGCTATTACTGAGA                   | nt 829-809   |           |      |
| FNF          | CAACACTTAGTATCAT                      | nt 2.443.126-2.443.126 | 653 bp |      |
| FN           | CAGATGCTAATACCTATA                    | nt 2.443.761-2.443.778 | 604 bp | [34] |
| FN-Probe     | Cy5-GGCTTCACCGACGTTCC-GH              | nt 2.443.229-2.443.248 |       |      |
| MHRHF        | GAAACGAGTGCTAGAATACATTC               | nt 18520-18542 |       |      |
| MHRHR        | AGCGGACTGAAGTGAAGCTTTAG               | nt 19124-19102 |       |      |
| Mhr-p37-RT-F | TATCTGAGGCGACCTGACTA                  | nt 768.070-768.092 | 89 bp | [15] |
| Mhr-p37-RT-R | ATTTTGCGCAATAGCATTGT                  | nt 816.070-835.070 |       |      |
| Mhr-p37-RT-Probe | 6FAM-CATCTTCTGGCTGACTCTCCTG-MGBNFQ      | nt 774.070-796.070 |       |      |

Target sequences for β-globin amplification—PC03/PC04 (110 bp). Target sequences for 16S rRNA of Mollicutes—GPO3/MGSO (270 bp), *H. pylori*—JW21/JW22 (138 bp), *F. nucleatum*—FNF/FNR (653 bp), *M. hyorhinis*—MHRHF/MHRHR (604 bp), and for p37 gene rRNA of *M. hyorhinis*—Mhr-p37-RT-F / Mhr-p37-RT-R / Mhr-p37-RT-Probe (89 bp).
liquid DAB. Sections were counterstained with haematoxylin. Immunohistochemical expression was observed by optical microscopy (40 ×), with 100 nuclei counted in 10 fields; every distinct brown stain was considered positive [37].

**Histopathological analyses**
A trained pathologist microscopically analysed H&E-stained slides. Specimens were examined and staged according to the guidelines of the Joint American Cancer Commission/International Union against Cancer/Classification of Malignant Tumours [38]. Metastatic disease was confirmed when, according to clinical records, lesions were detected in other organs or lymph nodes. The histological type of the tumour was classified as intestinal or diffuse [3].

**Statistical analysis**
Data analysis was performed using SPSS 20.0 (IBM, Corp., Armonk, NY, US). Categorical variables are presented as frequencies and percentages. We used the logistic regression model and odds ratio (OR) and calculated the respective 95% confidence intervals (CI). Variable selection was conducted in a stepwise manner and the unadjusted and adjusted OR were considered in the final model. The goodness of fit was verified by a Hosmer–Lemeshow test. Only significant variables (P < 0.05) were used in the final model unless the variable was biologically relevant. A standard Chi-square test was used to assess the strength of association between the presence of a study microorganism and certain clinicopathological characteristics. The non-parametric Mann–Whitney U test was used to evaluate the microbial load of *M. hyorhinis* in the case and control groups (positive and negative), using GraphPad Prism version 5.01 (GraphPad Software, Inc., La Jolla, CA, USA).

**Results**

**DNA extraction time, yield, and purity**
Dewaxing of FFPEs using xylol required 30 to 90 min compared to 1 min with mineral oil. The phenol–chloroform (EM1, EM2, and EM3) extractions were more laborious and time-consuming than those performed using alkaline buffer (EM4) and commercial kits (EM5 and EM6) (Table 2). Table 2 also presents the mean values of the total amount and purity of extracted DNA. EM1, EM2, and EM6 showed the best results according to DNA quantity (2.12, 2.10, and 2.09, respectively) and purity ratios (1.91, 1.92, and 1.98, respectively). Based on our evaluation, all 120 FFPE samples were dewaxed with mineral oil and DNA was extracted using EM6.

DNA extraction was validated by qualitative confirmation using PCR for the endogenous housekeeping control β-globin, with primers PC03/PC04 (110 bp). This reaction generates a small amplification product and is more suitable for DNA extracted from paraffin [22]. In total, 113 samples were positive for β-globin (case group, 73; control group, 40).

**DNA detection of Mollicutes, M. hyorhinis, H. pylori, and F. nucleatum according to patient gender and age**
Considering both the case and control groups, the mean patient age was 60 years (n = 120, Table 3), with a majority of male subjects (~60%). The case group consisted of predominantly males (~74%) and the control group of females (70%). Males had a ~fivefold higher risk (CI = 1.647–17.239) of developing gastric cancer (P = 0.004). Based on the median age, patients above 59 years of age had a 32-fold greater risk (CI = 8.112–129.376) of developing gastric cancer (P = 0.001). Table 3 also presents the presence and absence of our bacterial study species, PCR was performed to detect the DNA of Mollicutes in all the samples positive for the β-globin

| DNA extraction method     | 260/230* | 260/280* | DNA (ng/µL) |
|---------------------------|---------|---------|-------------|
| EM1 Xylol dewaxing material | 2.12    | 1.91    | 2.507       |
| EM1 Non-dewaxing material | 2.35    | 1.75    | 47          |
| EM2 Xylol dewaxing material | 2.10    | 1.92    | 475         |
| EM2 Non-dewaxing material | 2.47    | 1.66    | 168         |
| EM3 Xylol dewaxing material | 1.82    | 1.59    | 99          |
| EM3 Non-dewaxing material | 1.59    | 1.56    | 53          |
| EM4 Xylol dewaxing material | 0.38    | 1.19    | 800         |
| EM4 Non-dewaxing material | 0.38    | 1.27    | 431         |
| EM5 Xylol dewaxing material | 1.38    | 1.81    | 243         |
| EM5 Mineral oil dewaxing material | 1.24    | 1.94    | 112         |
| EM5 Non-dewaxing material | 1.69    | 2.06    | 183         |
| EM6 Xylol dewaxing material | 2.50    | 2.60    | 21          |
| EM6 Mineral oil dewaxing material | 2.09    | 1.98    | 82          |
| EM6 Non-dewaxing material | 2.96    | 2.78    | 16          |

*The wavelengths of 260/230 nm (ratio: 2.0–2.2) and 260/280 nm (ratio: 1.7–2.0) were considered acceptable for evaluation. In the 260/230 nm wavelength, EM1 and EM2 extraction methods and EM6 dewaxed with mineral oil show good DNA extraction. EM3, EM4, and EM5 extractions show low absorbance values, indicating contamination of salts (e.g. EDTA). At 260/280 nm, EM1, EM2 (dewaxed), EM5, and EM6 (dewaxed with mineral oil) present sufficient DNA purity. EM2 (Non-dewaxing material), EM3, EM4, and EM6 (xylol dewaxing material and non-dewaxing material) present insufficient DNA purity, indicating protein contamination and other organic compounds.
gene (n = 113); 10 samples were found to be positive for Mollicutes (8.8%), nine from patients with cancer (12.3%) and one from a healthy patient (2.5%). The presence of Mollicutes did not affect the development of gastric cancer, but was associated with a ~ twofold higher cancer risk factor compared with the control group.

For *H. pylori*, 15 samples were positive (13.3%): six from patients with cancer (8.2%) and nine from healthy patients (22.5%). The presence of *H. pylori* did not affect the cancer risk factor in the case group. *H. pylori* was strongly associated with the control group (OR = 0.130, CI 95% = 0.022–0.756). For *F. nucleatum*, 20 samples were found to be positive (16.7%): 19 from patients with cancer (26.0%) and one from a healthy patient (2.5%) (Table 3). The prevalence of *F. nucleatum* in the case group was significant (P = 0.045) and was associated with an 11-fold increase in the risk of developing gastric cancer (CI 95% = 1.057–105.521).

None of the samples tested positive for *M. hyorhinis* when using EM6 (data not shown). However, based on the qPCR results, eight samples from the case group (11.0%) and two samples from the control group (5.0%) were positive for *M. hyorhinis* (Table 3).

By employing a quantitative real-time PCR method, it was possible to quantify DNA as well as the microorganism load, represented as colony-forming units (CFU)/mL. The average loads of positive samples were approximately 100 to 108 CFU/mL of *M. hyorhinis* (Fig. 1).

In the case group, the mean load of *M. hyorhinis* was 4.44 × 107 CFU/mL (SD ± 6.85 × 107, minimum and maximum load of 0.14–1.68 × 108) and in the control group the mean load was 38.86 CFU/mL (SD ± 35.87, minimum and maximum load of 0.0–66.84). We could not detect a significant difference in microbial loads between the groups. There was no association between the OR (epidemiological association between outcome variables [patients with cancer × patients without cancer]) and *M. hyorhinis* detection rates (presence × absence) (OR = 0.671; CI = 0.050–8.946; Table 3).

### Table 3 Relationship between gender, age, and detection of microorganisms

| Variables          | Case n = 80 (%) | Control n = 40 (%) | Total n = 120 (%) | OR (Crude) P (Wald’s Test) OR (Adjusted) a P (Wald’s Test) OR (95% CI) |
|--------------------|----------------|--------------------|-------------------|-----------------------|-----------------------|
| **Gender**         |                |                    |                   |                       |                       |
| Male               | 59 (73.8)      | 12 (30.0)          | 71 (59.2)         | 0.001                 | 6.556                 | 0.005                 |
| Female             | 21 (26.2)      | 28 (70.0)          | 49 (40.8)         | (2.831–15.183)        | 31.000                | (1.647–17.239)        |
| **Age**            |                |                    |                   |                       |                       |                       |
| ≥ 59 years         | 62 (77.5)      | 4 (10.0)           | 66 (55.0)         | 0.001                 | 31.000                | 0.000                 |
| ≤ 58 years         | 18 (22.5)      | 36 (90.0)          | 54 (45.0)         | (7.931–98.753)        | (8.112–129.376)       |                       |
| **Mollicutes (PCR)**|               |                    |                   |                       |                       |                       |
| Positive           | 9 (12.3) b     | 1 (2.5)            | 10 (8.8) c        | 0.563 c               | 2.345                 | 0.622 c               |
| Negative           | 64 (87.7) b    | 39 (97.5)          | 103 (91.2) c      | (0.131–41.962) c      | (0.084–62.384) c      |                       |
| **H. pylori (PCR)**|               |                    |                   |                       |                       |                       |
| Positive           | 6 (8.2) b      | 9 (22.5)           | 15 (13.3) c       | 0.763 c               | 0.671                 | 0.978 c               |
| Negative           | 67 (91.3) b    | 31 (77.5)          | 98 (86.7) c       | (0.050–8.946) c       | (0.042–25.885) c      | 1.046                 |
| **F. nucleatum (qPCR)** |          |                    |                   |                       |                       |                       |
| Positive           | 19 (26.0) b    | 1 (2.5)            | 20 (16.7) c       | 0.080 c               | 0.353                 | 0.023 c               |
| Negative           | 54 (74.0) b    | 39 (97.5)          | 103 (83.3) c      | (0.353–0.110) c       | (0.022–0.756) c       | 0.130                 |
| **M. hyorhinis (qPCR)** |             |                    |                   |                       |                       |                       |
| Positive           | 8 (11.0) b     | 2 (5.0)            | 10 (8.8) c        | 0.021 c               | 11.357                | 0.045 c               |
| Negative           | 65 (89.0) b    | 38 (95.0)          | 103 (91.2) c      | (1.1443–89.397) c     | (1.1443–89.397) c     | 10.562                |

Positive—Detection of expected DNA product. Negative—Absence of expected DNA product.

a adjusted for *M. hyorhinis* and Mollicutes. The goodness of the adjustment was evaluated by the Hosmer–Lemeshow test (P = 0.914)
b Considering the case group, n = 73

c Considering n = 113 patients

OR, odds ratio; CI, confidence interval; qPCR, quantitative polymerase chain reaction

**Immunohistochemical detection of M. hyorhinis in FFPE samples of gastric tissues**

IHC was used to confirm the presence of *M. hyorhinis* in 120 samples prepared on slides using anti-*M. hyorhinis*...
antibodies (Fig. 2). Eight samples were positive for *M. hyorhinis* (6.7%), all belonging to the case group (*n* = 80).

The reactivity of the IHC technique was compared with the qPCR technique. We evaluated 73 samples by qPCR of which 50% tested positive following IHC detection (Fig. 3). Interestingly, a patient who was not examined using molecular techniques was found to be positive by IHC.

**Detection of mollicutes, *M. hyorhinis*, *H. pylori*, and *F. nucleatum* and associations with clinical factors in the case group**

Clinical and pathological factors and their association with microorganisms were compared (Table 4). The presence of Mollicutes showed a strong relationship with papillary arrays (*P* = 0.003). No statistically significant association was observed between the presence of *M. hyorhinis* and clinicopathological data. The detection of *H. pylori* was associated with metastasis (*P* = 0.024), lymphatic invasion (*P* = 0.033), diffused tumour (*P* = 0.028), and the GX/G1/G2 histopathological grade (*P* = 0.008).

The histopathological grading of cancer is classified as GX (where it was not possible to evaluate the degree of differentiation), G1 (well-differentiated), and G2 (moderately differentiated). The detection of *F. nucleatum* was
associated with advanced age > 59 (P = 0.030) and large tumour fragments > 4 cm (P = 0.053).

Coinfection profile and detection rate of mollicutes, *M. hyorhinis, F. nucleatum,* and *H. pylori* in the case and control groups

There was no difference in the abundance of Mollicutes, *M. hyorhinis,* or *F. nucleatum* between the case and controls groups (P = 0.117, P = 0.140, and P = 0.214, respectively). However, the abundance of *H. pylori* differed significantly between the case and control groups (P = 0.008). Coinfection profiles, the detection of two or more study microorganisms in the same clinical sample, were analysed in the two groups (Fig. 4). In the case group samples that were positive for Mollicutes (n = 73), six were positive for *M. hyorhinis* according to qPCR and IHC, respectively. The only sample positive for Mollicutes in the control group was negative for *M. hyorhinis* according to PCR. Mollicutes, *M. hyorhinis,* and *F. nucleatum* showed coinfection in two samples of the case group alone.

*H. pylori* and *F. nucleatum* showed coinfection only in one sample of the case group. *H. pylori* showed no coinfection with Mollicutes, but in the control group (n = 40) there was coinfection with *M. hyorhinis* and *H. pylori* in one patient. Overall, 56.25% of the case group samples and 70.00% of the control group samples were negative for any of the study microorganisms. The detection of *H. pylori* was higher in the control group, likely due to the favourable conditions created by congestion in the gastric wall that promotes acid secretion and inflammation. There was a significant difference in microorganism abundance between the groups (P = 0.001). Unlike *H. pylori,* the detection frequency of Mollicutes, *F. nucleatum,* and *M. hyorhinis* were considerably higher in the case group.

**Discussion**

Cancer has been a major research focus worldwide, with diverse risk factors associated with its development. In Brazil, stomach cancer mortality rates are male-biased, with the highest rates of occurrence observed in the Northeast region [2]. Brazil and other developing countries are disproportionately affected by infectious agents that are considered risk factors for developing cervical, liver, and stomach cancer [1]. Research into *M. hyorhinis* gained widespread momentum after its detection in human carcinomas and can potentially induce cell migration and metastasis, correlating with changes in phenotype and cellular karyotype. This change in cellular behaviour was associated with protein p37, present in its cell membrane [18, 39]. In general, mycoplasmas have been associated with malignant transformation in cell cultures and immortalisation of cells, promoting cell migration/invasion in immunosuppressed mice [4, 40]. Likewise, *F. nucleatum* has also been reported to cause tumour progression in immunosuppressed mice subjected to xenografts of patient-derived tumours [41].

The storage of tissues in paraffin blocks is convenient for transport, and also allows for retrospective examinations that could provide valuable information in epidemiology [22]. However, the recovery of nucleic acids in this type of material is difficult and with no methodological consensus in the literature with regards to optimal procedures. In the present study, six methods for DNA extraction from gastric fragments in FFPE blocks were compared for the detection of Mollicutes, *M. hyorhinis,* *F. nucleatum,* and *H. pylori.* Mineral oil dewaxing and commercial kits demonstrated the desired preferences, based on elapsed time, absence of toxic organic solvent reagents (such as phenol), and quality of target DNA after PCR [25, 27, 42]. Although extraction kits obtained a smaller amount of DNA, they allowed for a more efficient detection of targeted DNA, as residues that inhibit PCR efficacy are eliminated, thus reducing the possibility of sample contamination [43].

The DNA extraction methodology that demonstrated greater purity and recovery of nucleic acids was used for detecting the β-globin gene with PC03/PC04 primers, which was identified in 113 gastric tissue samples. FFPE samples are usually exposed to formaldehyde for a prolonged period of time, which modifies protein...
Table 4: Associations between the presence of Mollicutes, *H. pylori*, *F. nucleatum* and *M. hyorhinis* and clinicopathological factors

| Clinicopathological characteristics | Cases n = 73 (%) |
|------------------------------------|-----------------|
|                                    | Mollicutes (%)  | *H. pylori* (%)  | *F. nucleatum* (%) | *M. hyorhinis* (%) |
|                                    | PCR Positive | P  | PCR Positive | qPCR Positive | P  | qPCR Positive | IHC Positive | P  |
| Gender                            |              |    |              |               |    |              |              |    |
| Male                              | 54 (74.0) | 6 (11.1) | 0.781 | 4 (7.4) | 0.670 | 12 (22.2) | 0.142 | 4 (7.4) | 0.026 |
| Female                            | 19 (26.0) | 3 (15.8) | 2 (10.5) | 0.412 | 4 (21.1) |              |    | 4 (21.1) | 3 (14.3) | 0.446 |
| Age                               |              |    |              |               |    |              |              |    |
| ≤ 59                              | 18 (24.7) | 1 (5.6) | 0.553 | 2 (11.1) | 0.067 | 4 (22.2) | 0.030 | 1 (5.6) | 0.398 |
| > 59                              | 55 (75.3) | 8 (14.5) | 4 (7.3) | 1.250 | 15 (27.3) |              |    | 7 (12.7) | 8 (12.9) | 0.108 |
| Tumour size (cm)                  |              |    |              |               |    |              |              |    |
| ≤ 4                               | 24 (32.9) | 4 (16.7) | 0.430 | 2 (8.3) | 0.980 | 6 (25.0) | 0.053 | 3 (12.5) | 0.768 |
| > 4                               | 49 (67.1) | 5 (10.2) | 4 (8.2) |              | 13 (26.5) |              |    | 5 (10.2) | 4 (7.5) | 0.306 |
| TNM staging                       |              |    |              |               |    |              |              |    |
| I/II                              | 20 (27.4) | 3 (15.0) | 0.670 | 1 (5.0) | 0.538 | 2 (10.0) | 4.040 | 3 (15.0) | 0.497 |
| III/IV                            | 53 (72.6) | 6 (11.3) | 5 (9.4) | 17 (32.1) |              |    | 5 (9.4) | 6 (10.5) | 0.805 |
| Metastasis                        |              |    |              |               |    |              |              |    |
| Positive                          | 41 (56.2) | 7 (17.1) | 0.163 | 6 (14.6) | 0.004 | 12 (29.3) | 0.326 | 6 (14.6) | 0.255 |
| Negative                          | 32 (43.8) | 2 (6.3) | 0 (0.0) | 7 (21.9) |              |    | 2 (6.3) | 3 (8.8) | 0.763 |
| Regional lymph nodes              |              |    |              |               |    |              |              |    |
| NX                                | 3 (4.1) | 0 (0.0) | 0.476 | 0 (0.0) | 0.196 | 0 (0.0) | 4.336 | 0 (0.0) | 0.366 |
| N0                                | 28 (38.4) | 2 (7.1) | 0 (0.0) | 6 (21.4) |              |    | 2 (7.1) | 2 (6.9) | 0.064 |
| N1                                | 26 (35.6) | 3 (11.5) | 4 (15.4) | 8 (30.8) |              |    | 2 (7.7) | 2 (6.7) | 2 (6.7) |
| N2                                | 12 (16.4) | 3 (25.0) | 2 (16.7) | 5 (41.7) |              |    | 3 (25.0) | 1 (7.7) | 0.763 |
| N3                                | 4 (5.5) | 1 (25.0) | 0 (0.0) | 0 (0.0) | 1 (25.0) |              |    | 1 (25.0) | 0.543 |
| Lymphatic invasion                |              |    |              |               |    |              |              |    |
| Positive                          | 43 (58.9) | 7 (16.3) | 0.219 | 6 (13.9) | 0.033 | 13 (30.2) | 0.736 | 6 (13.9) | 0.327 |
| Negative                          | 30 (41.1) | 2 (6.7) | 0 (0.0) | 6 (20.0) |              |    | 2 (6.7) | 4 (12.5) | 0.543 |
| Vascular invasion                 |              |    |              |               |    |              |              |    |
| Positive                          | 11 (15.1) | 2 (18.2) | 0.522 | 2 (18.2) | 0.192 | 6 (54.5) | 3.421 | 1 (9.1) | 0.830 |
| Negative                          | 62 (84.9) | 7 (11.3) | 4 (6.5) | 13 (21.0) |              |    | 7 (11.3) | 6 (9.1) | 0.556 |
| Tumour type (Lauren’s Class)       |              |    |              |               |    |              |              |    |
| Intestinal                        | 39 (53.4) | 2 (5.1) | 0.110 | 2 (5.1) | 0.028 | 6 (15.4) | 2.609 | 3 (7.7) | 0.564 |
| Diffuse                           | 33 (45.2) | 7 (21.2) | 3 (9.1) | 13 (39.4) |              |    | 5 (15.2) | 6 (18.2) | 0.077 |
| Histopathological grade           |              |    |              |               |    |              |              |    |
| GX                                | 1 (1.4) | 0 (0.0) | 0.109 | 1 (100.0) | 0.008 | 10 (25.6) | 1.331 | 0 (0.0) | 0.649 |
| G1                                | 39 (53.4) | 2 (5.1) | 0 (0.0) | 2 (5.1) | 0 (0.0) | 3 (7.7) | 4 (8.9) | 0.892 |
| G2                                | 31 (42.5) | 6 (19.4) | 3 (8.7) | 9 (29.0) |              |    | 5 (16.1) | 4 (12.5) | 0.543 |
### Table 4 (continued)

| Clinicopathological characteristics | Cases n = 73 (%) | Mollicutes (%) | H. pylori (%) | F. nucleatum (%) | M. hyorhinis (%) |
|------------------------------------|----------------|---------------|---------------|------------------|------------------|
|                                    | PCR Positive | PCR Positive | qPCR Positive | qPCR Positive | IHC Positive | P | PCR Positive | P | PCR Positive | P | PCR Positive | P | PCR Positive | P |
| G3                                 | 2 (2.7)      | 0 (0.0)       | 0 (0.0)       | 0 (0.0)         | 0 (0.0)         | 2 (100.0) a |
| G4                                 | 0 (0.0)      | 0 (0.0)       | 0 (0.0)       | 0 (0.0)         | 0 (0.0)         | 0 (0.0) a |
| **Haemorrhage**                    |              |               |               |                  |                |
| Positive                           | 30 (41.1)    | 3 (10.0)      | 3 (10.0)      | 8 (26.7)        | 3 (10.0)        | 0.764 a |
| Negative                           | 43 (58.9)    | 6 (14.0)      | 3 (16.3)      | 11 (25.6)       | 5 (11.6)        | 0.93 a |
| **Inflammation**                   |              |               |               |                  |                |
| Positive                           | 17 (23.3)    | 3 (17.6)      | 3 (17.6)      | 5 (29.4)        | 2 (11.8)        | 0.805 a |
| Negative                           | 56 (76.7)    | 6 (10.7)      | 3 (5.4)       | 14 (25.0)       | 6 (10.7)        | 0.56 a |
| **Presence of eosinophils**        |              |               |               |                  |                |
| Positive                           | 13 (17.8)    | 3 (23.1)      | 2 (15.4)      | 4 (30.8)        | 2 (15.4)        | 0.333 a |
| Negative                           | 60 (82.2)    | 6 (10.0)      | 4 (6.7)       | 15 (25.0)       | 6 (10.0)        | 0.5 a |
| **Presence of neutrophils**        |              |               |               |                  |                |
| Positive                           | 14 (19.2)    | 2 (14.3)      | 2 (14.3)      | 2 (14.3)        | 1 (7.1)         | 0.475 a |
| Negative                           | 59 (80.2)    | 7 (11.9)      | 4 (6.8)       | 17 (28.9)       | 7 (11.9)        | 0.455 a |
| **Presence of macrophages**        |              |               |               |                  |                |
| Positive                           | 17 (23.3)    | 0 (0.0)       | 0 (0.0)       | 3 (17.6)        | 1 (5.9)         | 0.096 a |
| Negative                           | 56 (76.7)    | 9 (16.1)      | 6 (10.7)      | 16 (28.6)       | 7 (12.5)        | 0.096 a |
| **Tissue necrosis**                |              |               |               |                  |                |
| Positive                           | 16 (21.9)    | 4 (25.0)      | 0 (0.0)       | 5 (31.3)        | 2 (12.5)        | 0.192 a |
| Negative                           | 57 (78.1)    | 5 (8.8)       | 6 (10.5)      | 14 (24.6)       | 6 (10.5)        | 0.475 a |
| **Papillary arrangements**         |              |               |               |                  |                |
| Positive                           | 6 (8.2)      | 3 (50.0)      | 0 (0.0)       | 0 (0.0)         | 1 (16.7)        | 0.866 a |
| Negative                           | 67 (91.8)    | 6 (9.0)       | 6 (9.0)       | 19 (28.4)       | 7 (10.4)        | 0.62 a |
| **Tumour location**                |              |               |               |                  |                |
| Cardia                             | 4 (5.5)      | 1 (25.0)      | 0 (0.0)       | 0 (0.0)         | 1 (25.0)        | 0.881 a |
| Body                               | 25 (34.2)    | 4 (16.0)      | 4 (16.0)      | 6 (24.0)        | 2 (8.0)         | 0.12 a |
| Antrum                             | 43 (58.9)    | 4 (9.3)       | 2 (4.7)       | 13 (30.2)       | 5 (11.6)        | 0.12 a |
| Body and Antrum                    | 1 (1.4)      | 0 (0.0)       | 0 (0.0)       | 0 (0.0)         | 0 (0.0)         | 0.0 a |

* Considering case group, n = 80

qPCR, quantitative polymerase chain reaction; IHC, immunohistochemistry
Mollicutes was predominant in the diffuse type tumour, in moderately differentiated tumours (G2), and in patients with metastases. Although this association was not significant, *Mycoplasma* are considered opportunistic pathogens and cytogenetic modifiers [42, 43], with the ability to persist in the host for a prolonged period of time, favouring the gradual dysregulation of cell biology [46].

The Mollicutes showed a strong association with papillary tissue arrays (8.2% of patients). Previous research has also found Mollicutes associated with polyp formations in colon and mycoplasma infections [16]. Research suggests that *Mycoplasma* is able to stimulate cell transformation [11, 46]; production of lipid-associated membrane proteins (LAMPS) or macrophage-activating lipopeptide-2 (MALP-2), which induce the MyD88 pathway and NF-κB activation through toll-like receptors 1, 2, and 6 [47, 48]; induce major inflammatory events via nitric oxide synthase (iNOS) [48, 49]. Cell aberrations induced during *Mycoplasma* infection may also originate from their capacity to block host DNA repair, as seen in in vitro assays with the protein DnaK, isolated from *M. fermentans*. This chaperone binds to poly (ADP-ribose) polymerase (PARP-1) or in the p53 regulator, impairing the host’s DNA repair capacity and leading to p53 silencing [50]. Moreover, p53 silencing may stimulate chromosomal instability and cell transformation [40, 51]. Blocking of the host’s DNA repair capacity occurs during *H. pylori* infection, which induces NF-κB expression, leading to chronic inflammation and atrophic gastritis, metaplasia, and dysplasia [20, 52].

Persistent *H. pylori* infection has been classified as carcinogenic to humans (Group 1) by the International Agency for Research on Cancer [53]. In the present study, *H. pylori* infection was detected in control individuals, which can be expected in a stomach microenvironment altered by surgery and can trigger the development of ulcers, making this site even more favourable for the establishment of this bacteria [54, 55]. The clinical aspects of infection vary depending on location, host susceptibility, bacterial strain (not all strains of *H. pylori* are oncogenic), environmental influence, and host habits [56]. Approximately 10% to 15% of individuals with *H. pylori* infection may develop severe inflammation and peptic ulcers [57], as well as gastric adenocarcinoma (1–3%) or lymphoma (0.1%) [58].

In our study, *H. pylori* was significantly associated with metastasis (*P* = 0.024) and lymphatic invasion (*P* = 0.033). In a pervious study, *H. pylori* has been associated with the expression of CagA, the most important virulence factor of *H. pylori*, which induces the robust activation of SHP-2 and ERK. CagA also promotes tumorigenesis by inducing gastric epithelial cell

![Figure 4: Detection rate of Mollicutes (PCR), *H. pylori* (PCR), *F. nucleatum* (qPCR), and *M. hyorhinis* (qPCR and IHC), from gastric tissue. The diagonal lines on the white background represent Mollicutes (Molli) in the case and control group (1.25% and 2.50%, respectively). Dark-grey represents *H. pylori* (Hp) in the case and control group (6.25% and 20.00%, respectively). Light-grey represents *F. nucleatum* (Fn) in the case and control group (20.00% and 2.50%, respectively). The diagonal lines on the grey background represent *M. hyorhinis* (Mhyo-qPCR/HIC) in the case and control group (5.00% and 2.50%, respectively). Coinfection of the case samples: 7.50% with Mollicutes and *M. hyorhinis* (brick with black background), 2.50% of Mollicutes and *F. nucleatum* (brick with white background), and 1.25% of *F. nucleatum* and *H. pylori* (light-grey squares). In the control samples, only one coinfection of *M. hyorhinis* and *H. pylori* was observed (2.50%, dark-grey squares). qPCR, quantitative polymerase chain reaction; IHC, immunohistochemistry. Mann Whitney, assuming P-value ≤ 0.05.](image-url)
mobility and proliferation [59]. In the present study, *H. pylori* was located in non-cardia regions of the stomach, similar to previous studies [60]. The presence of *H. pylori* was marginally associated with differentiated (G2) \( (P=0.008) \) and diffused type \( (P=0.028) \) tumours. These tumour phenotypes have also been correlated with *H. pylori* in a previous study [61]. Moreover, *H. pylori* has also been associated with the dysregulation of pepsinogen I (PG1) and pepsinogen 2 (PG2) [62], decreased gastric glands [63], and expression of interleukin (IL)-10, leading to an anti-inflammatory response that attenuates the immune system’s response [64].

The silencing of the human immune response against tumorigenesis has also been reported during *F. nucleatum* infection, that contributes to carcinogenesis by inducing preneoplastic conditions [9]. Although *F. nucleatum* is predominant in colorectal tumours, it is also well established in gastric tumour tissues, where it is associated with poor survival rates by promoting metastasis and diffuse-type tumour progression [65]. In the present study, *F. nucleatum* was predominant in the stomach and body and antrum regions in patients with metastasis and lymphatic invasion, similar to *H. pylori*. However, *H. pylori* is reportedly an initiator of the Correa cascade and *F. nucleatum* is not related to chronic gastritis, so rather than being an initiator, *F. nucleatum* may be involved in the final stages of the classical Correa cascade [65].

Diffuse-type tumours are strongly associated with E-cadherin dysregulation. It is well known that *F. nucleatum* promotes carcinogenesis by linking FadA to E-cadherin, activating β-catenin and the Wnt pathway, inducing the expression of several oncogenic properties [66]. FadA expression, in addition to being associated with E-cadherin expression, is also strongly associated with host DNA damage, cell proliferation, chk2 expression, S-phase cells, and an increase in tumour size [66]. In our study, the presence of *F. nucleatum* was significant at tumour size > 4 cm \( (P=0.053) \). Tumour size and TNM stage III/IV have also been associated with *F. nucleatum* in other studies [67]. In addition to FadA mechanisms, TLR4 activation by *F. nucleatum* LPS can plausible lead to the activation of Myd88 and NF-κB, which leads to oncogenic overexpression of miR21, resulting in dysregulated growth and infiltration of tumour tissue. According to our results, the presence of *F. nucleatum* was significant in patients > 59 years of age \( (P=0.30) \), which could be due to lower global long interspersed element-1 (LINE-1) DNA methylation [65], and epigenetic silencing of the MLH1 repair protein caused by cytokine modulation (e.g., IL-6 e TNF) [68]. This suggest that *F. nucleatum* may be associated with epigenetic alterations, such as global DNA hypomethylation. Similarly, *M. hyorhinis* has been described as an intracellular agent that could modulate the host epigenetic machinery through nucleomodulins [69].

A possible mechanism of tumour pathogenicity of *M. hyorhinis* may be due to the activity of its methyltransferases, in which three types have already been described: Mhy1 and Mhy2, which promote methylation of CG, and Mhy3, which acts on GATC sites leading to aberrant methylation patterns in its entire genome [69]. Hypermethylation of the GATC site is related to the silencing of specific genes, such as *APC, TP53, BRCA2, KRAS, PTEN, SMAD4*, and *VEGFC*. GATC methylation is uncommon in human cells and may emerge during *M. hyorhinis* infection, suggesting a new type of epigenetic infection-dependent marker [69]. Other mycoplasmas, such as *M. penetrans* and *M. pulmonis*, can also methylate GC sites, indicating that methylation may be a significant factor for these bacteria to adapt and survive in the host [70]. Aberrant methylation frequently contributes to malignant cellular phenotypes [4]. Furthermore, *H. pylori* infection can induce the aberrant methylation of genes such as tp53 and the Wnt pathway—factors strongly associated with gastric adenocarcinoma development [71]. Similar to *H. pylori*, *M. hyorhinis* was more biased toward the G2 tumour and diffused type, unlike what has been found in previous studies [17], and was localised mainly in the stomach body. This adenocarcinoma mainly affects older adults and can lead to a permanent inflammatory process and the gradual alteration of cells [64].

*M. hyorhinis* could not be detected by conventional PCR, probably because its PCR product was too large and DNA from paraffin specimens tends to come in small fragments [27]. According to qPCR analysis, 11.0% of the case group samples were positive for *M. hyorhinis*; among these, six were paired with the positive Mollicutes PCRs. The association of *M. hyorhinis* with gastric cancer development has previously been reported in studies showing that 50% of FFPE gastric cancer samples were positive for *M. hyorhinis* by PCR or IHC detection targeting p37 [16, 72]. qPCR also detected the DNA of *M. hyorhinis* in 5.0% of the samples from the control group. However, the samples that were positive for *M. hyorhinis* did not match the positive samples for Mollicutes. Indeed, other species of the class Mollicutes have been described in samples of gastric disease [11].

The detection of *M. hyorhinis* by the IHC revealed that ~10% of the samples in the case group were positive. In the case group, 8 samples positive for *M. hyorhinis* were detected, 4 of which were detected by both the IHC and qPCR methods. In the control group, two samples were positive for *M. hyorhinis* and were detected by qPCR, whereas IHC failed to detect the protein p37. The IHC could be a better method for target detection when
considering that the formaldehyde in blocks may damage the M. hyorhinis DNA composed of approximately 74% A+T bases, while formalin preserves the protein morphology and inactivates proteolytic enzymes that favour the IHC methodology. Nevertheless, the qPCR method showed a higher detection sensitivity, indicating that the minimal amounts of DNA remain intact even under the action of chemical solutions and storage time; truncated proteins can also be difficult to detect by IHC [73]. These differences between tests have been observed in other studies [37]. The samples positive for M. hyorhinis by IHC were associated with gastric cancer risk, as reported in previous investigations [16].

If the detection of M. hyorhinis by IHC and qPCR was possible, then we assume that the assessed individuals were exposed to this microorganism at some level. Our current understanding of how M. hyorhinis infects humans remains poor, though pathogenic and environmental factors undoubtedly play a role. Indeed, the opportunistic character of Mollicutes, mainly antigenic variation, oxidative stress induction, and a limited host immune response, allow these bacteria to establish permanent infections and settle in different ecological niches [46]. Several Mollicute species are typically found in animals but have been detected in humans without symptoms of disease, though some species may cause disease, particularly in immunocompromised individuals [10].

In the present study, M. hyorhinis was detected in gastric samples belonging to 59 patients, presenting tumour invasion (TNM stage III/IV) and lymphatic invasion. The M. hyorhinis p37 membrane protein is described to interact with TLR4 and induce the rapid expression of several genes linked to inflammation, in addition to promoting the progression of cancer toward metastasis, as it facilitates PI3k phosphorylation and activation of the PI3k-AKT pathway [21, 46]. The p37 protein induces the expression of HRAS (known capacity in mycoplasmas), resulting in PI3k phosphorylation, which regulates cell motility [74]. In prostate cells, p37 has the ability to induce matrix metalloproteinase-2 (MMP-2) superactivity and thereby increases EGFR phosphorylation, this can potentially result in cells acquiring a greater potential for dissemination, thus inducing metastasis [46]. This indicates that the ability of these microorganisms to colonise and promote inflammation in the gastric environment is strongly associated with the modulation of mechanisms expressed in local cells.

Conclusion
This study was limited to exploring the clinicopathological characteristics of gastric tumour tissues and their associations with microorganisms, opening doors for the exploration of in vitro methods to analyse which microbial factors induce different cell signalling pathways, metabolic changes, or extracellular responses in cell matrix models.

Collectively, our findings indicate that FFPE tissue samples improved our previous understanding with regards to the strength of association of Mollicutes, M. hyorhinis, F. nucleatum, and H. pylori in gastric cancer. H. pylori alone may not lead to all the changes necessary for neoplastic development, but the complex feedback of the microbiotic community can contribute to the conditions of the disease. F. nucleatum is frequently found in biopsies of patients with gastric cancer, but there are still many unanswered questions about its role in the development of the disease.

Mollicutes are often underestimated as potential factors that drive diverse pathological aspects of certain diseases, but the association of mollicutes with the formation of papillary arrays demonstrates its importance in terms of observed malignant phenotypes. Mollicutes of animal origin represent a wide field of classical opportunistic bacteria capable of inducing human disturbances. The detection of M. hyorhinis in Brazilian populations with stomach cancer is an important finding. Therefore, this study contributes to a better understanding of the role of these bacteria in the development of gastric cancer and its malignant transformation.

Abbreviations
BA: Bahia; FFPE: Formalin-fixed paraffin-embedded; IHC: Immunohistochemistry; H&E: Haematoxylin-eosin; EM: Extraction method; PK: Proteinase K; CFU: Colony-forming unit; GX: Not possible to evaluate the degree of tumour differentiation; G1: Tumour well-differentiated; G2: Tumour moderately differentiated; IARC: International Agency for Research on Cancer.

Acknowledgements
The authors would like to acknowledge the Pathological Anatomy and Cytopathology Service for their assistance with samples and pathological analyses of patient data. Jim Hesson revised the manuscript (https://www.academicenshionsolutions.com).

Authors’ contributions
CNA: conceptualisation, data analysis, designing all methodology, investigation during laboratory work, writing the original draft, and reviewing the final manuscript. ATA: data analysis, designing molecular biology methodology, and performing laboratory investigations. MSB: data analysis, designing immunological tests, performing laboratory investigations. JCPLA: interpretation of immunohistochemistry results, performing laboratory investigations. GBC: conceptualisation, methodology review, and reviewing the final manuscript. LMM: interpretation of histopathology results, methodology review, and reviewing the final manuscript. JT: conceptualisation, methodology review, and reviewing the final manuscript. All authors have read and approved the manuscript.

Funding
This work was supported by grants from the São Paulo Research Foundation (FAPESP) (Grant Number 2014/05071-6) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brasil (CAPES) (Finance Code...
References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

2. INCA (Instituto de Câncer José Alencar Gomes da Silva). Estimativa 2020. Incidência do câncer no Brasil. 2019.

3. Lauren P. The Two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.

4. Eyvazi S, Vostakolaei MA, Dilmaghani A, Borumandi O, Hejazi MS, Kahrobaee et al. The oncogenic roles of bacterial infections in development of cancer. Microb Pathog. 2020;141(1):104019.

5. Brennan CA, Garrett WS. Fusobacterium nucleatum—symbiont, opportun ist and oncobacterium. Nat Rev Microbiol. 2019;17(3):156–66.

6. Tjalsma H, Boleij A, Marchesi JR, Dutilh BE. A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol. 2012;10(8):575–82.

7. Yu T, Guo F, Yu Y, Sun T, Han J, Kryczek I, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell. 2017;170(3):548–63.

8. Ito M, Kanno S, Nosho K, Sukawa Y, Mitsuhashi K, Kurihara H, et al. Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway. Int J Cancer. 2015;137(6):1258–68.

9. Gur C, Ibrahim Y, Isaacson B, Yamin R, Abed J, Gamliel M, et al. Binding of the Fap2 protein of fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumours from immune cell attack. Immunity. 2015;42(2):344–55.

10. Baseman JB, Tully JG. Mycoplasmas: sophisticated, reemerging, and burdened by their notoriety. Emerg Infect Dis. 1997;3(1):21–32.

11. Kwon HJ, Kang JO, Cho SH, Kang HB, Kang KA, Kim JK, et al. Presence of human mycoplasma DNA in gastric tissue samples from Korean chronic gastritis patients. Cancer Sci. 2004;95(4):311–5.

12. Brown DR, May M, Bradbury JM, Johansson K-E, Neimark H. Mycoplas- matales. Bergey’s Manual of Systematic Bacteriology. 2015:1–2.

13. Yang H, Qu L, Ma H, Chen L, Liu W, Liu C, et al. Mycoplasma hyorhinis infection in gastric carcinoma and its effects on the malignant phenotypes of gastric cancer cells. BMC Gastroenterol. 2010;10(1):132.

14. Kornsnap JD, Tsur M, Tarshis M, Rottem S, Brenner T. Mycoplasma hyorhinis induces proinflammatory responses in mice lymphocytes. J Basic Microbiol. 2015;55(5):679–84.

15. Tocqueville V, Ferré S, Nguyen NHP, Kempf I, Marois-Crèhãna C. Multilocus sequence typing of Mycoplasma hyorhinis strains identified by a real-time TaqMan PCR assay. J Clin Microbiol. 2014;52(5):1664–71.

16. Huang S, Li JY, Wu J, Meng L, Shou CC. Mycoplasma infections and differ ent human carcinomas. World J Gastroenterol. 2001;7(2):266–9.

17. Zhang J, Wang Y, Shou C, Xu G, Xin C, Wu J, et al. Detection of Mycoplasma hyorhinis in gastric cancer. Zhonghua Yi Xue Za Zhi. 2002;82(4):961–5.

18. Gomersall AC, Phan HA, Laconne S, Li SF, Parish RW. The mycoplasma hyorhinis p37 protein rapidly induces genes in fibroblasts associated with inflammation and cancer. PLoS ONE. 2015;10(10):1–24.

19. Gong M, Meng L, Jiang B, Zhang J, Yang H, Wu J, et al. p37 from Myco- plasma hyorhinis promotes cancer cell invasiveness and metastasis through activation of MMP-2 and followed by phosphorylation of EGFR. Mol Cell Ther. 2008;7(3):530–7.

20. Fu L, Xie C. A lucid review of Helicobacter pylori-induced DNA damage in gastric cancer. Helicobacter. 2019;24(5):1–9.

21. Duan H, Qu L, Shou C. Activation of EGFR-F3KR-AKT signaling is required for Mycoplasma hyorhinis-promoted gastric cancer cell migration. Cancer Cell. 2014;15(1):11–9.

22. Greer CE, Wheeler CM, Manos MM. Sample preparation and PCR amplification from Paraffin-embedded tissues. Cold Spring Harb Protoc. 1994;3(6):113–22.

23. Cao W, Hashibe M, Rao JY, Morgenstern H, Zhang ZF. Comparison of methods for DNA extraction from paraffin-embedded tissues and buccal cells. Cancer Detect Prev. 2003;27(5):397–404.

24. Rabelo-Gonçalves E, Roesler B, Guardia AC, Milan A, Hara N, Escanhoela C, et al. Evaluation of five DNA extraction methods for detection of H. Pylori in formalin-fixed paraffin-embedded (FFPE) liver tissue from patients with hepatocellular carcinoma. Pathol Res Pract. 2014;210(3):142–6.

25. Lin J, Kennedy SH, Savrovsky T, Rogers J, Kemnitz JW, Xu A, et al. High-quality genomic DNA extraction from formalin-fixed and paraffin-embedded deparaffinized using mineral oil. Anal Biochem. 2009;395(2):266–75.

26. Mesquita RA, Anzai EK, Oliveira RN, Nunes FD. Evaluation of 3 methods of DNA extraction from paraffin-embedded tissue for the amplification of oncotype DX and estrogen receptor genes. Anal Biochem. 2010;400(1):121–6.

27. Alvarez-Aldana A, Martínez JW, Sepúlveda-Arias JC. Comparison of five procedures to extract DNA from paraffin-embedded tissues for the detection of human papillomavirus. Pathol Res Pract. 2015;211(2):150–5.

28. Green MR, Sambrook J. Isolation of high-molecular-weight DNA from mammalian tissues using proteinase K and phenol. Cold Spring Harb Protoc. 2017;2017(3):260–4.

29. Saki RK, Scharf S, Falloona F, Mullis KB, Horn GT, Erlitch HA, et al. Enzymatic amplification of -globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science (80- ). 1985;230:1350–4.

30. Friis NF. Mycoplasmas cultivated from the respiratory tract of Danish pigs. Acta Vet Scand. 1971;12(1):69–79.

31. Tully JG. Culture medium formulation for primary isolation and mainte nance of Mycoplasma hyorhinis. J Vet Med B Infect Dis. 1992;58(8):2606–15.

32. Gomersall AC, Phan HA, Iacuone S, Li SF, Parish RW. The mycoplasma hyorhinis p37 protein rapidly induces genes in fibroblasts associated with inflammation and cancer. PLoS ONE. 2015;10(10):1–24.

33. Yang H, Qu L, Ma H, Chen L, Liu W, Liu C, et al. Mycoplasma hyorhinis infection in gastric carcinoma and its effects on the malignant phenotypes of gastric cancer cells. BMC Gastroenterol. 2010;10(1):132.

34. Kornsnap JD, Tsur M, Tarshis M, Rottem S, Brenner T. Mycoplasma hyorhinis induces proinflammatory responses in mice lymphocytes. J Basic Microbiol. 2015;55(5):679–84.

35. Tocqueville V, Ferré S, Nguyen NHP, Kempf I, Marois-Crèhãna C. Multilocus sequence typing of Mycoplasma hyorhinis strains identified by a real-time TaqMan PCR assay. J Clin Microbiol. 2014;52(5):1664–71.

36. Huang S, Li JY, Wu J, Meng L, Shou CC. Mycoplasma infections and differ ent human carcinomas. World J Gastroenterol. 2001;7(2):266–9.

37. Zhang J, Wang Y, Shou C, Xu G, Xin C, Wu J, et al. Detection of Mycoplasma hyorhinis in gastric cancer. Zhonghua Yi Xue Za Zhi. 2002;82(4):961–5.
34. Timenetsky J, Santos LM, Buzinhani M, Metchiffo E. Detection of multiple mycoplasma infection in cell cultures by PCR. Braz J Med Biol Res. 2006;39(7):907–14.

35. Coffey J, Choudhry M, Shlossman M, Makin IRS, Singh VK. Multiplex real-time PCR detection and relative quantification of periodontal pathogens. Clin Exp Dent Res. 2016;3(2):183–92.

36. Kornspon JD, Tarshis M, Rottem S. Invasion of melanoma cells by Mycoplasma mycoides. Cancer Res. 2004;64(1):377–82.

37. Duan H, Chen L, Qu L, Yang H, Song SW, Han Y, et al. Mycoplasma Hyorhinis: enhancement by protease treatment. Infect Immun. 2010;78(2):611–7.

38. Brierley JD, Gospodarowicz MK, Wittkend C. TNM Classification of malignant tumours. In: Brierley JD, Gospodarowicz MK, Wittkend C, editors. Union for international cancer control, 8th ed (2017).

39. Urbanek C, Goodson S, Chang M, Porvaznik S, Sakamoto N, Li CZ, et al. Detection of antibodies directed at M. hyorhinis p37.1 in sera from horses with newly diagnosed prostate cancer. BMC Cancer. 2011;11(1).

40. Zella D, Currelli S, Benedetti F, Krishnan S, Cocchi F, Latinoic OS, et al. Mycoplasma promotes malignant transformation in vivo, and its DnaK, a bacterial chaperon protein, has broad oncogenic properties. Proc Natl Acad Sci USA. 2018;115(51):E2005–14.

41. Bullman S, Pedamallu CS, Sicinska E, Clancy TE, Cai D, Neuberg D, et al. Analysis of Fusobacterium persistence and antibiotic resistance in colorectal cancer. Science (80-) 2017;358(6369):1443–8.

42. Gilbert MTP, Haselkorn T, Bunce M, Sanchez JJ, Lucas SB, Jewell LD, et al. The isolation of nucleic acids from fixed, paraffin-embedded tissues—which methods are useful when? PLoS ONE. 2007;2(6).

43. Okello JBA, Zurek J, Devault AM, Kuch M, Okwi AL, Sewankambo NK, et al. Comparison of methods in the recovery of nucleic acids from archival formalin-fixed paraffin-embedded autopsy tissues. Anal Biochem. 2010;400(1):110–7.

44. Yow MA, Tabrizi SN, Severi G, Bolton DM, Pedersen J, Longano A, et al. Detection of infectious organisms in archival prostate cancer tissues. BMC Cancer. 2014;14:579.

45. Wroblewski LE, Peek RM, Coburn LA. The role of the microbiome in gastrointestinal cancer. Gastroenterol Clin North Am. 2016;45(3):543–56.

46. Benedetti F, Currelli S, Zella D. Mycoplasmas–host interaction: mechanisms of inflammation and association with cellular transformation. Microorganisms. 2020;8(9):1–21.

47. Wang Y, Wang G, Li Y, Chen Y, Shao J, Niu X, et al. Mmme-derived lipid-associated membrane proteins activate TLR2, MyD88, and IRAK4. Sci Rep. 2017;7(1):1–9.

48. Yu QQ, Wang H, Huo JT, An XF, Gao P, Jiang ZZ, et al. Suppression of NF-κB pathway via TLR2, MyD88, and IRAK4. Sci Rep. 2017;7(1):1–9.

49. Galanos C, Gumenscheimer M, Mühlradt PF, Jirillo E, Freudenberg MA. Analysis of Fusobacterium persistence and antibiotic resistance in colorectal cancer. Scientific Reports. 2017;38:6369.

50. Chernov AV, Reyes L, Xu Z, Gonzalez B, Golovko G, Petersen S, et al. Mycoplasma CG- and GATC-specified DNA methyltransferases selectively and efficiently methylate the host genome and alter the epigenetic landscape in human cells. Epigenetics. 2015;10(April):303–18.

51. Chmiela M, Karwowska Z, Gonciarz W, Allushi B, Stazek P. Host pathogen interactions in Helicobacter pylori related gastric cancer. World J Gastroenterol. 2017;23(9):1521–40.

52. Kusters JG, Van Vliet AHM, Kuijpers EJP. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev. 2006;19(3):449–90.

53. Mnich E, Kowalewicz-Kulbat M, Sicinska P, Hinc K, Obuchowski M, Tzaczek P. Host pathogen interactions in Helicobacter pylori related gastric cancer. World J Gastroenterol. 2016;22(33):7536–58.

54. Kuo SH, Chen LT, Lin CW, Yeh KH, Shun CT, Tzeng YS, et al. Expression of the CagA protein and CagA-signaling molecules predict Helicobacter pylori dependence of early-stage gastric DLBCB. Blood. 2017;129(2):188–98.

55. Ramaswamy A, Sasauchi K, Inoue M, Tsugane S. Different etiological role of Helicobacter pylori (Hp) infection in carcinogenesis between differentiated and undifferentiated gastric cancers: a nested case-control study using IgG titer against Hp surface antigen. Acta Oncol (Madr). 2008;47(3):360–5.

56. Rajalingam K, Schreck R, Rapp UR, Albert Š. Ras oncogenes and their downstream targets. PLoS ONE. 2007;2(6).

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.